Roles of NRXN1 in neuropsychiatric disorders: from genetic lesion to molecular mechanism

AI Summary

NRXN1 genetic variants confer risk across a spectrum of neuropsychiatric disorders, notably schizophrenia and autism spectrum disorder, implicating synaptic dysfunction in pathogenesis.
An isoform-dependent excitation-inhibition imbalance hypothesis for NRXN1 in autism reconciles both increased and decreased excitation-inhibition ratios among affected individuals.
NRXN1 deletions and alternative splicing provide molecular links between schizophrenia and autism, while therapeutic approaches remain limited and research challenges persist.

Front Neurosci. 2026 May 13;20:1808921. doi: 10.3389/fnins.2026.1808921. eCollection 2026.

ABSTRACT

Numerous neuropsychiatric disorders frequently exhibit overlapping genetic risk factors, implying the molecular basis for their comorbidity. Nevertheless, the pathogenesis of these disorders remains elusive, particularly regarding how genetic variations impair the physiological function of risk genes and contribute to disease phenotypes. Neurexin 1 protein, encoded by NRXN1 gene, belongs to the neurexin family of presynaptic adhesion molecules. And neurexin 1 is involved in synaptogenesis and the maintenance of synaptic action. Genetic variations of NRXN1 have been demonstrated to be associated with a spectrum of neuropsychiatric disorders. Herein, this review focuses on the most recent and relevant literature concerning the genetic and molecular mechanisms through which NRXN1 variants contribute to the pathogenesis of neuropsychiatric disorders, particularly schizophrenia and autism spectrum disorder. Among them, we propose the isoform-dependent excitation-inhibition imbalance hypothesis of NRXN1 in autism spectrum disorder. And this hypothesis may account for both the elevated and decreased excitation-inhibition ratios observed in diverse individuals with autism spectrum disorder. Moreover, both schizophrenia and autism spectrum disorder involve deletions and alternative splicing of NRXN1, offering molecular evidence for their comorbidity. Then, we analyzed and summarized the current research status of NRXN1 in other neuropsychiatric disorders, including attention-deficit hyperactivity disorder, insomnia, epilepsy, suicide, and depression. Additionally, available limited researches on NRXN1-targeted therapeutic strategies and associated pharmacological studies are also incorporated. Finally, we discussed existing challenges in NRXN1 research within the context of neuropsychiatric disorders and proposed potential avenues to overcome these obstacles.

PMID:42211283 | PMC:PMC13212319 | DOI:10.3389/fnins.2026.1808921

Document this CPD